UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 82

Sortiert nach

Monoclonal antibody treatments for rheumatoid arthritis

Expert opinion on biological therapy, 2013-09, Vol.13 (9), p.1257-1272

2013

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Blood, 2012-07, Vol.120 (3), p.560-568

2012

Link zum Volltext

Verfügbarkeit prüfen

Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells

Immunity (Cambridge, Mass.), 2007-12, Vol.27 (6), p.965-974

2007

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience

Blood, 2012-08, Vol.120 (7), p.1470-1472

2012

Link zum Volltext

Verfügbarkeit prüfen

A new generation of protein display scaffolds for molecular recognition

Protein science, 2006-01, Vol.15 (1), p.14-27

2006

Link zum Volltext

Verfügbarkeit prüfen

ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials

Journal of clinical oncology, 2013-04, Vol.31 (12), p.1522-1529

2013

Link zum Volltext

Verfügbarkeit prüfen

The bispecific immunoligand ULBP2‐aCEA redirects natural killer cells to tumor cells and reveals potent anti‐tumor activity against colon carcinoma

International journal of cancer, 2014-06, Vol.134 (12), p.2829-2840

2014

Link zum Volltext

Verfügbarkeit prüfen

The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells

Journal of experimental & clinical cancer research, 2012-05, Vol.31 (1), p.47-47, Article 47

2012

Link zum Volltext

Verfügbarkeit prüfen

The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2

Oncology reports, 2013-03, Vol.29 (3), p.1061-1065

2013

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Blood, 2015-06, Vol.125 (26), p.4024-4031

2015

Link zum Volltext

Verfügbarkeit prüfen

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Blood, 2014-03, Vol.123 (11), p.1658-1664

2014

Link zum Volltext

Verfügbarkeit prüfen

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report

Journal of medical case reports, 2011-05, Vol.5 (1), p.215-215, Article 215

2011

Link zum Volltext

Verfügbarkeit prüfen

Recombinant proteins in rheumatology – recent advances

New biotechnology, 2011-09, Vol.28 (5), p.502-510

2011

Link zum Volltext

Verfügbarkeit prüfen

Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients

Molecular therapy, 2013-04, Vol.21 (4), p.895-903

2013

Link zum Volltext

Verfügbarkeit prüfen

Multi-Specific Antibodies for Cancer Immunotherapy

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2014-08, Vol.28 (4), p.331-343

2014

Link zum Volltext

Verfügbarkeit prüfen

Altern in der Fremde: Neue Herausforderungen an die soziale Arbeit

Rothe, Achim

1992

Link zum Volltext

Verfügbarkeit prüfen

Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis

European journal of haematology, 2020-04, Vol.104 (4), p.291-298

2020

Link zum Volltext

Verfügbarkeit prüfen

In vitro display technologies reveal novel biopharmaceutics

The FASEB journal, 2006-08, Vol.20 (10), p.1599-1610

2006

Link zum Volltext

Verfügbarkeit prüfen

18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma

Leukemia & lymphoma, 2014-04, Vol.55 (4), p.811-816

2014

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma

Leukemia & lymphoma, 2013-10, Vol.54 (10), p.2144-2148

2013

Link zum Volltext

Verfügbarkeit prüfen

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

Blood, 2014-12, Vol.124 (21), p.1753-1753

2014

Link zum Volltext

Verfügbarkeit prüfen

CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity

Transplantation, 2013-08, Vol.96 (3), p.e16

2013

Link zum Volltext

Verfügbarkeit prüfen

Updated phase I data of AFM13: A bispecific tandem antibody (TandAb) in relapsed/refractory (R/R) Hodgkin lymphoma (HL)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3025-3025

2014

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation

Blood, 2012-11, Vol.120 (21), p.2743-2743

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Englisch
(58)
Deutsch
(25)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(35)
Science & Technology
(35)
Humans
(32)
Animals
(15)
Female
(13)
Male
(11)
Adult
(10)
Aged
(9)
Biological And Medical Sciences
(9)
Hematology
(9)
Immunology
(9)
Middle Aged
(9)
Oncology
(9)
Hodgkin Disease - Drug Therapy
(8)
Mice
(7)
Young Adult
(7)
Biochemistry & Molecular Biology
(6)
Biotechnology & Applied Microbiology
(6)
Flow Cytometry
(6)
Medical Sciences
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Monoclonal antibody treatments for rheumatoid arthritis

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells

Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience

A new generation of protein display scaffolds for molecular recognition

ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability

The bispecific immunoligand ULBP2‐aCEA redirects natural killer cells to tumor cells and reveals potent anti‐tumor activity against colon carcinoma

The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells

The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report

Recombinant proteins in rheumatology – recent advances

Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients

Multi-Specific Antibodies for Cancer Immunotherapy

Altern in der Fremde: Neue Herausforderungen an die soziale Arbeit

Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis

In vitro display technologies reveal novel biopharmaceutics

18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma

Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity

Updated phase I data of AFM13: A bispecific tandem antibody (TandAb) in relapsed/refractory (R/R) Hodgkin lymphoma (HL)

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation

Suchergebnisse filtern